Clindamycin Phosphate Patent Expiration
Clindamycin Phosphate was first introduced by Pfizer Inc
Clindamycin Phosphate Patents
Given below is the list of patents protecting Clindamycin Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xaciato | US11129896 | Topical formulations and treatments | Sep 22, 2036 | Organon Llc |
| Xaciato | US12303563 | Topical formulations and treatments | Sep 22, 2036 | Organon Llc |
| Clindesse | US9789057 | Pharmaceutical delivery system | Dec 02, 2026 | Padagis Us |
| Evoclin | US7141237 | Pharmaceutical foam |
Feb 03, 2024
(Expired) | Quagen |
| Evoclin | US7374747 | Pharmaceutical foam |
Jan 23, 2024
(Expired) | Quagen |
| Clindesse | US6899890 | Bioadhesive drug delivery system |
Apr 27, 2023
(Expired) | Padagis Us |
| Clindagel | US6387383 | Topical low-viscosity gel composition |
Aug 03, 2020
(Expired) | Bausch |
| Cleocin | US6495157 | Intravaginal clindamycin ovule composition |
Jul 20, 2020
(Expired) | Pfizer |
| Clindesse | US5993856 | Pharmaceutical preparations and methods for their administration |
Nov 17, 2017
(Expired) | Padagis Us |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Clindamycin Phosphate's patents.
Latest Legal Activities on Clindamycin Phosphate's Patents
Given below is the list recent legal activities going on the following patents of Clindamycin Phosphate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) | 20 Mar, 2025 | US11129896 |
| Email Notification | 20 Mar, 2025 | US11129896 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Mar, 2025 | US11129896 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Mar, 2025 | US11129896 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 29 Dec, 2021 | US11129896 |
| Email Notification Critical
| 29 Dec, 2021 | US11129896 |
| Correspondence Address Change Critical
| 27 Dec, 2021 | US11129896 |
| Patent Issue Date Used in PTA Calculation Critical
| 28 Sep, 2021 | US11129896 |
| Recordation of Patent Grant Mailed Critical
| 28 Sep, 2021 | US11129896 |
| Email Notification Critical
| 09 Sep, 2021 | US11129896 |
Clindamycin Phosphate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Clindamycin Phosphate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) | Changchun GeneScience Pharmaceutical Co., Ltd. | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE1 |